Adjuvant Therapy in Endometrial Cancer with Special Emphasis and Reference to Indian Setting

  • Lavanya Gurram
  • Umesh MahantshettyEmail author
  • Supriya Chopra
  • Sudeep Gupta
  • Jaya Ghosh
  • Seema Gulia
  • Amita Maheshwari
  • TS Shylasree
Part of the following topical collections:
  1. Controversies to Consensus : Recent advances


The incidence of endometrial cancer (EC) is on the rise in India. The median age at presentation is lesser than the Western population. Majority of the patients present in early stages with excellent overall survival rates after surgery. Adjuvant therapy is essential in high-risk stages I–III for improving outcomes. The quality and extent of surgery, and complete histopathological information are important factors for outcome and tailoring adjuvant therapy. Depending on patients and histopathological factors, various risk groups have been defined for prognostication and defining adjuvant therapy. Adjuvant therapy including external radiation, vaginal brachytherapy, chemotherapy and combined chemoradiotherapy has been tried depending on various risk groups. The purpose of this article is to review and interpret and update the results of existing literature on adjuvant therapy in EC with a special focus on Indian reports and standards.


Endometrial cancer Adjuvant therapy Radiation therapy Chemotherapy 


Compliance with Ethical Standards

Conflict of interest



  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefGoogle Scholar
  2. 2.
    ICMR. Three-year report of population based cancer registries 2012–2014, Chapter 2. Bengaluru: NCDIR-NCRP(ICMR); 2016.Google Scholar
  3. 3.
    Balasubramaniam G, Sushama S, Rasika B, Mahantshetty U. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pac J Cancer Prev. 2013;14(2):977–80.CrossRefGoogle Scholar
  4. 4.
    Koshiyama M, Konishi I, Fujii S. Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer (review). Cancer J. 1998;11(277–283):54.Google Scholar
  5. 5.
    Ellenson LH, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ. Chapter 9 Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s pathology of the female genital tract. 6th ed. Berlin: Springer; 2011. p. 393–452.Google Scholar
  6. 6.
    Mahantshetty U, Aggarwal A, Ganesh B, Saoba S, Mulla S, Engineer R, Chopra S, Maheshwari A, Kerkar R, Shylasree TS, Ghosh J. Clinical outcome of early-stage endometroid adenocarcinoma: a tertiary cancer center experience. Int J Gynecol Cancer. 2013;23(8):1446–52.CrossRefGoogle Scholar
  7. 7.
    Kim HS, Suh DH, Kim MK, Chung HH, Park NH, Song YS. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol. 2012;42(5):405–12.CrossRefGoogle Scholar
  8. 8.
    Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118(1):14–8.CrossRefGoogle Scholar
  9. 9.
    Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Barakat R, Pearl ML, Sharma SK. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012;30(7):695.CrossRefGoogle Scholar
  10. 10.
    Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, Fowler WC. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008;199(4):360-e1.CrossRefGoogle Scholar
  11. 11.
    Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2–30.CrossRefGoogle Scholar
  12. 12.
    Aalders J, Abeler VE, Kolstad P, Onsrud MA. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56(4):419–27.PubMedGoogle Scholar
  13. 13.
    Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.CrossRefGoogle Scholar
  14. 14.
    Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631–8.CrossRefGoogle Scholar
  15. 15.
    Nout RA, Smit VT, Putter H, Juergenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MS, van Bunningen BN. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–23.CrossRefGoogle Scholar
  16. 16.
    Astec T. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN. 5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46.CrossRefGoogle Scholar
  17. 17.
    Vance S, Burmeister C, Rasool N, Buekers T, Elshaikh MA. Salvage versus adjuvant radiation treatment for women with early-stage endometrial carcinoma: a matched analysis. Int J Gynecol Cancer. 2016;26(2):307–12.CrossRefGoogle Scholar
  18. 18.
    Creutzberg CL, Van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys. 2015;91(3):530–9.CrossRefGoogle Scholar
  19. 19.
    Kong A, Simera I, Collingwood M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol. 2007;18:1595–604.CrossRefGoogle Scholar
  20. 20.
    Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107:1823–30.CrossRefGoogle Scholar
  21. 21.
    Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, Colombo A, Fossati R. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266.CrossRefGoogle Scholar
  22. 22.
    Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):226–33.CrossRefGoogle Scholar
  23. 23.
    Hogberg T, Signorelli M, De Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31.CrossRefGoogle Scholar
  24. 24.
    Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS, Kim JW, Salani R, DiSilvestro PA, Burke JJ. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019;17:JCO-18.Google Scholar
  25. 25.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D’Amico R, Fyles A. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2018;19:295–309 (2019; 20(9):1273–1285).CrossRefGoogle Scholar
  26. 26.
    Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O’Malley DM, Spirtos NM. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317–26.CrossRefGoogle Scholar
  27. 27.
    Shih KK, Milgrom SA, Abu-Rustum NR, Kollmeier MA, Gardner GJ, Tew WP, Barakat RR, Alektiar KM. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. Gynecol Oncol. 2013;128(3):535–9.CrossRefGoogle Scholar
  28. 28.
    Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D’Souza D, Souhami L, Small W Jr, Gaur R. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86(1):83–90.CrossRefGoogle Scholar
  29. 29.
    Klopp Ah, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during Pelvic IMRT: NRG Oncology—RTOG 1203. J Clin Oncol. 2018;36(24):2538–44.CrossRefGoogle Scholar
  30. 30.
    Small W Jr, Beriwal S, Demanes DJ, Dusenbery KE, Eifel P, Erickson B, Jones E, Rownd JJ, Jennifer F, Viswanathan AN, Gaffney D. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012;11(1):58–67.CrossRefGoogle Scholar
  31. 31.
    Kumar UP, Yathiraj PH, Sharan KT, Kamath A, Singh A, Reddy SA, Alurkar P, Fernandes DJ, Mamidipudi VS. Patterns of recurrence, long-term survival and toxicity analysis of endometrial adenocarcinoma patients reclassified under the recent ESMO–ESGO–ESTRO stratification: seven-year results from a single institution. Int J Gynecol Cancer. 2018;28(5):854–60.CrossRefGoogle Scholar
  32. 32.
    Sunil RA, Bhavsar D, Shruthi MN, Kunikullaya US, Vyas RK, Parikh A, Mehta MJ, Patel PN. Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate-and high-risk cases of endometrium carcinoma. J Contemp Brachytherapy. 2018;10(2):105.CrossRefGoogle Scholar
  33. 33.
    Rathod PS, Shakuntala PN, Pallavi VR, Kundaragi R, Shankaranand B, Vijay CR, Devi KU, Bafna UD. The risk and pattern of pelvic and para aortic lymph nodal metastasis in patients with intermediate and high risk endometrial cancer. Indian J Surg Oncol. 2014;5(2):109–14.CrossRefGoogle Scholar
  34. 34.
    Somashekhar SP, Jaka RC, Zaveri SS. Prospective randomized study comparing robotic-assisted hysterectomy and regional lymphadenectomy with traditional laparotomy for staging of endometrial carcinoma–initial Indian experience. Indian J Surg Oncol. 2014;5(3):217–23.CrossRefGoogle Scholar
  35. 35.
    Ansar PP, Ayyappan S, Mahajan V. Prospective nonrandomized comparative study of laparoscopic versus open surgical staging for endometrial cancer in India. Indian J Surg Oncol. 2018;9(2):133–40.CrossRefGoogle Scholar
  36. 36.
    Thomas V, Thomas A, Sebastian A, Chandy R, Peedicayil A. Inadequately staged endometrial cancer: a clinical dilemma. Indian J Surg Oncol. 2018;9(2):166–70.CrossRefGoogle Scholar
  37. 37.
    Wortman BG, Bosse T, Nout RA, Lutgens LC, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KA, Verhoeven-Adema KW, Smit VT. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol. 2018;151(1):69–75.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  • Lavanya Gurram
    • 1
  • Umesh Mahantshetty
    • 1
    Email author
  • Supriya Chopra
    • 1
  • Sudeep Gupta
    • 2
  • Jaya Ghosh
    • 2
  • Seema Gulia
    • 2
  • Amita Maheshwari
    • 3
  • TS Shylasree
    • 3
  1. 1.Department of Radiation Oncology, 1123, Homi Bhabha Block, Tata Memorial HospitalGynecology Disease Management Group, Tata Memorial CentreMumbaiIndia
  2. 2.Department of Medical OncologyGynecology Disease Management Group, Tata Memorial CentreMumbaiIndia
  3. 3.Department of Gynecology OncologyGynecology Disease Management Group, Tata Memorial CentreMumbaiIndia

Personalised recommendations